RankingsPricing
  1. US-listed companies
  2. Citius Pharmaceuticals, Inc.
  3. Financials
  4. Stock-based compensation

Citius Pharmaceuticals, Inc.CTXR

Market cap
$10.7M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Sep 30, 202412+78.94%
Sep 30, 20237+69.40%
Sep 30, 20224+168.45%
Sep 30, 20211+81.13%
Sep 30, 20201+12.19%
Sep 30, 20191-8.17%
Sep 30, 20181-20.97%
Sep 30, 20171+34.76%
Sep 30, 20161+50.56%
Sep 30, 20150

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)